IP Library Granted Patent US 9,428,576
Granted Patent B2
US 9,428,576 · App. 14/839,744 · Granted Aug 30, 2016

Anti-p40 antibodies systems and methods

Inventors: David Tacha (San Ramon, CA); Weimin Qi (Martinez, CA)
Assignee: Biocare Medical, LLC
C07K16/18C07K16/28G01N33/5017G01N33/574G01N33/577G01N33/57484G01N33/57488C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,428,576
App. No.
14/839,744
Granted
Aug 30, 2016
Kind
B2
Abstract

The present invention is related to the anti-p40 antibodies, kits, cocktails, and use of anti-p40 antibodies for detection of cancer.

Claims (34)

1. An isolated antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under ATCC Patent Deposit Designation No. PTA-120163 or isolated antigen binding fragment of the isolated antibody, wherein the antibody or antigen binding fragment thereof specifically binds p40 comprising SEQ ID NO:4.

2. A composition comprising the isolated antibody or isolated antigen binding fragment thereof of claim 1 and at least one additional isolated antibody or isolated antigen binding fragment thereof, wherein the at least one additional isolated antibody or isolated antigen binding fragment thereof specifically binds to an antigen selected from the group consisting of DSG-3, CK4, CK5, Napsin A, HMWCK, p504S, CK5/14, CK7/18, CK8/18, Uroplakin II, Uroplakin III and GATA-3.

3. The isolated antibody or isolated antigen binding fragment thereof of claim 1 , wherein the isolated antibodies or isolated antigen binding fragments thereof comprises a light chain variable region comprising the amino acid

sequence encoded by a nucleic acid sequence consisting of SEQ ID NO: 2 and a heavy chain variable region comprising the amino acid sequence encoded by a nucleic acid sequence consisting of SEQ ID NO: 1.

4. The composition according to claim 2 wherein the isolated antigen binding fragment and the at least one additional isolated antibody or isolated antigen binding fragment of the isolated antigen binding fragment are derived from at least two different species.

5. The composition according to claim 4 wherein said at least two different species is selected from a group consisting of mouse, rabbit, goat, horse, chicken and human.

6. The composition according to claim 2 wherein the isolated antibody or isolated antigen binding fragment thereof and the at least one additional isolated antibodies or

isolated antigen binding fragments thereof each bind specifically to proteins selected from a group consisting of:

p40 and DSG-3 and CK5 and Napsin A;

p40 and DSG-3 and CK5;

p40 and Napsin A;

p40 and HMWCK and p504s;

p40 and p504s and CK5/14;

p40 and CK5/14 and CK7/18;

p40 and CK5/14 and CK8/18;

p40 and Uroplakin II and Uroplakin III; and

p40 and Uroplakin II and Uroplakin III and GATA-3.

7. The composition according to claim 2 wherein the isolated antibody or the isolated antigen binding fragment thereof and said at least one additional isolated antibodies or isolated antigen binding fragments thereof each bind

specifically to proteins selected from a group consisting of:

p40 and DSG-3 and Napsin A;

p40 and DSG-3; and

p40 and CK5.

8. A kit comprising:

the isolated antibody or isolated antigen binding fragment thereof of claim 1 ; and

an antibody detection reagent of said isolated antibody or isolated antigen binding fragment thereof of claim 1 when bound to the p40 antigen.

9. The isolated antibody or isolated antigen binding fragment thereof of claim 1 , wherein the isolated antibody or isolated antigen is conjugated with a label.

10. The antibody according to claim 9 wherein said label is selected from a group consisting of a radioactive element, magnetic particles, radioisotope, fluorescent dye, enzyme, toxin, signal, stain, detection enzymes, horseradish peroxidase (HRP), alkaline phosphatase (AP), beta-galactosidase, chromogens, Fast Red, 3,3′-diaminobenzidine, 3-amino-9-ethylcarbazole, 5-bromo-4-chloro-3-indolyl phosphate, 3,3′,5,5′-tetramethylbenzidine, 5-bromo-4-chloro-3-indolyl-β-D-glucuronide, and any combination thereof.

11. A method for detecting p40 in a biological sample comprising the steps of:

(a) providing the kit of claim 8 ; and

(a) detecting binding of said isolated antibody or said isolated antigen binding fragment thereof with the p40 antigen with an immunoassay comprising:

(i) contacting the biological sample with the isolated antibody or isolated antigen binding fragment thereof produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under ATCC Patent Deposit Designation No. PTA-120163, wherein the antibody or antigen fragment thereof specifically binds p40 comprising SEQ ID NO:4 to form a complex; and

(ii) detecting the complex with the antibody detecting element provided in the kit, wherein the immunoassay is selected from the group consisting of immunohistochemistry (IHC), IHC of FFPE, IHC of frozen-tissue sections, immunocytochemistry, and ELISA.

12. The method for detecting p40 in a biological sample according to claim 11 wherein said biological sample comprises lung tissue, bladder tissue, breast tissue, and prostate tissue.

13. The method for detecting p40 in a biological sample according to claim 11 wherein said biological sample is selected from a group consisting of a normal tissue, neoplastic tissue, bladder tissue, kidney tissue, ovarian tissue, thyroid tissue, endometrial tissue, renal tissue, tonsil tissue, pancreas tissue, colon tissue, lymph node tissue, neoplastic pancreatic tissue, stomach tissue, prostate tissue, lung tissue and breast tissue.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jun 25, 2026
From: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
To: BIOCARE MEDICAL LLC
Reel/Frame 075082/0723 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE NAME INSERTING THE COMMA BEFORE LLC PREVIOUSLY RECORDED ON REEL 36679 FRAME 728. ASSIGNOR(S) HEREBY CONFIRMS THE ORIGINAL ASSIGNMENT. Recorded Feb 24, 2026
From: TACHA, DAVID; QI, WEIMAN
To: BIOCARE MEDICAL, LLC
Reel/Frame 074989/0009 →
SECURITY INTEREST Recorded Dec 9, 2021
From: BIOCARE MEDICAL LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 058344/0799 →
RELEASE OF SECURITY INTEREST Recorded Dec 9, 2021
From: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
To: BIOCARE MEDICAL LLC
Reel/Frame 058351/0058 →
SECURITY INTEREST Recorded Aug 25, 2017
From: BIOCARE MEDICAL LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 043401/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2015
From: TACHA, DAVID; QI, WEIMIN
To: BIOCARE MEDICAL LLC
Reel/Frame 036679/0728 →
Continuity (3)
Continuation PCTUS2014019705 · Feb 28, 2014
Provisional Application 61770956 · Feb 28, 2013
Related Publication 20160009795A1 · Jan 14, 2016